Skip to main content
Log in

Risk Reduction Strategies in Ischaemic Stroke

The Role of Antiplatelet Therapy

  • Review Article
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

Abstract

Stroke is a common and serious disorder, and is a leading cause of disability and death in adults. Transient ischaemic attacks are now recognised as being common precursors of stroke, with a high risk of subsequent vascular events. The majority of strokes are ischaemic in origin, and are typically due to atherothrombosis/microatheromatosis involving a large or small cerebral blood vessel or to an embolic event. Owing to the diffuse nature of atherothrombosis, these patients are at risk of ischaemic events in other vascular beds. Options for treating patients with acute ischaemic stroke are very limited; therefore prevention is a key strategy for reducing the risk of recurrent stroke and other vascular events. Treatment of risk factors such as hypertension, diabetes mellitus, smoking and obesity is an important approach for stroke prevention. Platelets are involved in the development of thrombi and emboli, making antiplatelet therapy an important preventive strategy. Antiplatelet agents are effective in preventing recurrent ischaemic stroke and other vascular ischaemic events, such as myocardial infarction and vascular death. In some cases, anticoagulants may be effective in preventing ischaemic stroke recurrence. Carotid endarterectomy can reduce stroke risk in patients with moderate- or high-grade carotid artery stenosis. Choosing the most appropriate therapy for the individual patient is key to optimising stroke prevention.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I
Table II
Table III
Table IV

Similar content being viewed by others

References

  1. Mohr JP, Albers GW, Amarenco P, et al. Etiology of stroke. Stroke 1997; 28: 1501–6

    Article  PubMed  CAS  Google Scholar 

  2. Lammie GA. Hypertensive cerebral small vessel disease and stroke. Brain Pathol 2002; 12: 358–70

    PubMed  Google Scholar 

  3. De Jong G, Kessels F, Lodder J. Two types of lacunar infarcts: further arguments from a study on prognosis. Stroke 2002; 33: 2072–6

    Article  PubMed  Google Scholar 

  4. Albers GW, Caplan LR, Easton JD, et al. Transient ischemic attack: proposal for a new definition. N Engl J Med 2002; 347: 1713–6

    Article  PubMed  Google Scholar 

  5. Johnston SC, Gress DR, Browner WS, et al. Short-term prognosis after emergency department diagnosis of TIA. JAMA 2000; 284: 2901–6

    Article  PubMed  CAS  Google Scholar 

  6. Hankey GJ. Long-term outcome after ischaemic stroke/transient ischaemic attack. Cerebrovasc Dis 2003; 16 Suppl. 1: 14–9

    Article  PubMed  Google Scholar 

  7. Droste DW, Ringelstein EB. Evaluation of progression and spread of atherothrombosis. Cerebrovasc Dis 2002; 13 Suppl. 1: 7–11

    Article  PubMed  Google Scholar 

  8. Sacco RL, Shi T, Zamanillo MC, et al. Predictors of mortality and recurrence after hospitalized cerebral infarction in an urban community: the Northern Manhattan Stroke Study. Neurology 1994; 44: 626–34

    Article  PubMed  CAS  Google Scholar 

  9. Hardie K, Hankey GJ, Jamrozik K, et al. Ten-year survival after first-ever stroke in the Perth Community Stroke Study. Stroke 2003; 34: 1842–6

    Article  PubMed  Google Scholar 

  10. Bauters C. Atherothrombosis: the same process for different arterial territories? Ann Cardiol Angeiol (Paris) 2002; 51: 177–80

    Article  CAS  Google Scholar 

  11. Yuan C, Zhang SX, Polissar NL, et al. Identification of fibrous cap rupture with magnetic resonance imaging is highly associated with recent transient ischemic attack or stroke. Circulation 2002; 105: 181–5

    Article  PubMed  Google Scholar 

  12. Carr S, Farb A, Pearce WH, et al. Atherosclerotic plaque rupture in symptomatic carotid artery stenosis. J Vasc Surg 1996; 23: 755–65

    Article  PubMed  CAS  Google Scholar 

  13. Corti R, Badimon JJ. Biologic aspects of vulnerable plaque. Curr Opin Cardiol 2002; 17: 616–25

    Article  PubMed  Google Scholar 

  14. Harker LA. Therapeutic inhibition of platelet function in stroke. Cerebrovasc Dis 1998; 8 Suppl. 5: 8–18

    Article  PubMed  Google Scholar 

  15. Marquardt L, Ruf A, Mansmann U, et al. Course of platelet activation markers after ischemic stroke. Stroke 2002; 33: 2570–4

    Article  PubMed  CAS  Google Scholar 

  16. DiNapoli M, Papa F, the Villa Pini Stroke Data Bank Investigators. Inflammation, hemostatic markers, and antithrombotic agents in relation to long-term risk of new cardiovascular events in first-ever ischemic stroke patients. Stroke 2002; 33: 1763–71

    Article  PubMed  Google Scholar 

  17. Blann AD, Landray MJ, Lip GY. ABC of antithrombotic therapy: an overview of antithrombotic therapy. BMJ 2002; 325: 762–5

    Article  PubMed  Google Scholar 

  18. UK-TIA Study Group. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 1991; 54: 1044–54

    Article  Google Scholar 

  19. Lai SM, Alter M, Friday G, et al. A multifactorial analysis of risk factors for recurrence of ischemic stroke. Stroke 1994; 25: 958–62

    Article  PubMed  CAS  Google Scholar 

  20. Collins R, MacMahon S. Blood pressure, antihypertensive drug treatment and the risks of stroke and coronary artery disease. Br Med Bull 1994; 50: 272–98

    PubMed  CAS  Google Scholar 

  21. Leys D, Deplanque D, Mounier-Vehier C, et al. Stroke prevention: management of modifiable vascular risk factors. J Neurol 2002; 249: 507–17

    Article  PubMed  Google Scholar 

  22. Ginsberg HN. Treatment for patients with the metabolic syndrome. Am J Cardiol 2003; 91(7A): 29–39E

    Article  Google Scholar 

  23. Straus SE, Majumdar SR, McAlister FA. New evidence for stroke prevention: scientific review. JAMA 2002; 288: 1388–95

    Article  PubMed  Google Scholar 

  24. Hart RG, Halperin JL, McBride R, et al. Aspirin for the primary prevention of stroke and other major vascular events. Arch Neurol 2000; 57: 326–32

    Article  PubMed  CAS  Google Scholar 

  25. Steering Committee of the Physicians’ Health Study Research Group. Final report on the aspirin component of the ongoing Physicians’ Health Study. N Engl J Med 1989; 321: 129–35

    Article  Google Scholar 

  26. Eidelman RS, Hebert PR, Weisman SM, et al. An update on aspirin in the primary prevention of cardiovascular disease. Arch Intern Med 2003; 163: 2006–10

    Article  PubMed  Google Scholar 

  27. Byington RP, Davis BR, Plehn JF, et al. Reduction of stroke event with pravastatin: the Prospective Pravastatin Pooling (PPP) project. Circulation 2001; 103: 387–92

    Article  PubMed  CAS  Google Scholar 

  28. Waters DD, Schwartz GG, Olsson AG, et al. Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy. Circulation 2002; 106: 1690–5

    Article  PubMed  CAS  Google Scholar 

  29. Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004: 363: 757–67

    Article  Google Scholar 

  30. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97

    Google Scholar 

  31. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7–22

    Article  Google Scholar 

  32. Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2002; 342: 145–53

    Google Scholar 

  33. Sleight P, Yusuf S, Pogue J, et al. Blood pressure reduction and cardiovascular risk in HOPE study. Lancet 2001; 358: 2130–1

    Article  PubMed  CAS  Google Scholar 

  34. Progress Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6, 105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033–41

    Article  Google Scholar 

  35. Coull BM, Williams LS, Goldstein LB, et al. Anticoagulants and antiplatelet agents in acute ischemic stroke: report of the Joint Stroke Guideline Development Committee of the American Academy of Neurology and the American Stroke Association. Stroke 2002; 33: 1934–42

    Article  PubMed  CAS  Google Scholar 

  36. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71–86

    Article  Google Scholar 

  37. Grundmann K, Jaschonek K, Kleine B, et al. Aspirin non-responder status in patients with recurrent cerebral ischemic attacks. J Neurol 2003; 250: 63–6

    Article  PubMed  CAS  Google Scholar 

  38. Gum PA, Kottke-Marchant K, Welsh PA, et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003; 41: 961–5

    Article  PubMed  CAS  Google Scholar 

  39. Alberts MJ, Bergman DL, Molner E, et al. Antiplatelet effect of aspirin in patients with cerebrovascular disease. Stroke 2004; 35: 175–8

    Article  PubMed  CAS  Google Scholar 

  40. Valles J, Santos MT, Aznar J, et al. Erythrocyte promotion of platelet reactivity decreases the effectiveness of aspirin as an antithrombotic therapeutic modality: the effect of low-dose aspirin is less than optimal in patients with vascular disease due to prothrombotic effects of erythrocytes on platelet reactivity. Circulation 1998; 97: 350–5

    Article  PubMed  CAS  Google Scholar 

  41. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclo-oxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001; 345: 1809–17

    Article  PubMed  CAS  Google Scholar 

  42. MacDonald TM, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 2003; 361: 573–4

    Article  PubMed  CAS  Google Scholar 

  43. Howes LG, Kram H. Selective cyclo-oxygenase-2 inhibitors and myocardial infarction: how strong is the link? Drag Saf 2002; 25: 829–35

    Article  CAS  Google Scholar 

  44. Hankey GJ, Sudlow CLM, Dunbabin PW. Thienopyridines or aspirin to prevent stroke and other serious vascular events in patients at high risk of vascular disease? A systematic review of the evidence from randomized trials. Stroke 2000; 31: 1779–84

    Article  PubMed  CAS  Google Scholar 

  45. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329–39

    Article  Google Scholar 

  46. Hacke W. From CURE to MATCH: ADP receptor antagonists as the treatment of choice for high-risk atherothrombotic patients. Cerebrovasc Dis 2002; 13 Suppl. 1: 22–6

    Article  PubMed  CAS  Google Scholar 

  47. CURE Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494–502

    Article  Google Scholar 

  48. Steinhubl SR, Berger PB, Mann JT, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288: 2411–20

    Article  PubMed  CAS  Google Scholar 

  49. Diener HC, Cunha L, Forbes C, et al. European Stroke Prevention Study 2: dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143: 1–13

    Article  PubMed  CAS  Google Scholar 

  50. Ticlopidine Aspirin Stroke Study Group. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 1989; 321: 501–7

    Article  Google Scholar 

  51. Gorelick PB, Richardson D, Kelly M, et al. Aspirin and ticlopidine for prevention of recurrent stroke in Black patients: a randomized trial. JAMA 2003; 289: 3005–7

    Article  Google Scholar 

  52. He J, Whelton PK, Vu B, et al. Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials. JAMA 1998; 280: 1930–5

    Article  PubMed  CAS  Google Scholar 

  53. Serebraany VL, Malinin AI, Eisert RM, et al. Risk of bleeding complications with antiplatelet agents: meta-analysis of 338, 191 patients enrolled in 50 randomized controlled trials. Am J Hematol 2004; 75: 40–7

    Article  Google Scholar 

  54. Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ 2000; 321: 1183–7

    Article  PubMed  CAS  Google Scholar 

  55. Zakarija A, Bandarenko N, Pandey DK, et al. Clopidogrel-associated TTP: an update of pharmacovigilance efforts conducted by independent researchers, pharmaceutical suppliers, and the Food and Drug Administration. Stroke 2004: 35: 533–7

    Article  PubMed  Google Scholar 

  56. Albers GW, Amarenco P, Easton JD, et al. Antithrombotic and thrombolytic therapy for ischemic stroke. Chest 2001; 119(1 Suppl. ): 300S–20S

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

Dr Alberts is a consultant and has received honoraria and research funding from Sanofi, Bristol-Myers Squibb and Boehringer-Ingelheim.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Mark J. Alberts.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Alberts, M.J., Atkinson, R. Risk Reduction Strategies in Ischaemic Stroke. Clin. Drug Investig. 24, 245–254 (2004). https://doi.org/10.2165/00044011-200424050-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00044011-200424050-00001

Keywords

Navigation